Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 8/20 | 0.41 |
| ▸ | F10 | P00742 | 8/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 4/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13715459 | 0.86 | FOLH1 (0.42) | F2F10PRSS1GAAALDH1A1 | |
| SCHEMBL3873634 | 0.84 | GAA (0.47) | GAAALDH1A1MAPTESR1AR | |
| SCHEMBL434211 | 0.81 | ESR1 (0.54) | F2F10PRSS1ALDH1A1MAPT | |
| SCHEMBL13715201 | 0.81 | ESR1 (0.54) | F2F10PRSS1ALDH1A1MAPT | |
| SCHEMBL13715340 | 0.81 | ESR1 (0.54) | F2F10PRSS1ALDH1A1MAPT | |
| SCHEMBL31522502 | 0.80 | MAPT (0.41) | GAAALDH1A1MAPTHTTESR1 | |
| SCHEMBL2495278 | 0.79 | F10 (0.50) | F2F10PRSS1GAAALDH1A1 | |
| SCHEMBL2503014 | 0.79 | F10 (0.50) | F2F10PRSS1GAAALDH1A1 | |
| SCHEMBL27830823 | 0.79 | F10 (0.50) | F2F10PRSS1GAAALDH1A1 | |
| SCHEMBL13093046 | 0.79 | ESR1 (0.44) | GAAALDH1A1ESR1ARESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572934-B2 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572934-B2 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090111859-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090111859-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2008130514-A1 | SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS | AMGEN INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111859-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | F2 4203/4885F10 3795/4885PRSS1 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.